Search Results for "Insomnia"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Insomnia. Results 201 to 210 of 226 total matches.

Two New Drugs for Chronic ITP

   
The Medical Letter on Drugs and Therapeutics • Feb 09, 2009  (Issue 1305)
with romiplostim have included headache, dizziness, insomnia, myalgia, abdominal pain, dyspepsia and paresthesia ...
Romiplostim (Nplate - Amgen), a recombinant fusion protein injected subcutaneously, and eltrombopag (Promacta - GlaxoSmithKline), a non-peptide taken orally, have been approved by the FDA for treatment of chronic immune thrombocytopenic purpura (ITP) refractory to corticosteroids, immunoglobulins and/or splenectomy.
Med Lett Drugs Ther. 2009 Feb 9;51(1305):10-1 |  Show IntroductionHide Introduction

Omadacycline (Nuzyra) - A New Tetracycline Antibiotic

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
, diarrhea, constipation, headache, hypertension, insomnia, and hepatic transaminase elevations. Nausea ...
The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Med Lett Drugs Ther. 2019 May 20;61(1572):74-7 |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
Adverse Effects – Dyskinesia, constipation, dizziness, hallucinations, and insomnia have been reported ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction

Treatment of Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004  (Issue 1197)
flashes compared to placebo. All of these drugs can cause nausea, diarrhea, headache, insomnia ...
Estrogen is the most effective treatment for menopausal vasomotor symptoms (hot flashes), but the Women's Health Initiative study found that women who took estrogen plus a progestin for more than 5 years were at increased risk for myocardial infarction, stroke, pulmonary emboli, deep vein thrombosis, breast cancer, and possibly dementia. Are there effective alternatives?
Med Lett Drugs Ther. 2004 Dec 6;46(1197):98-9 |  Show IntroductionHide Introduction

Arformoterol (Brovana) for COPD

   
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007  (Issue 1264)
skeletal muscle tremor and cramping, insomnia, tachycardia, decreases in serum potassium and increases ...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)
Med Lett Drugs Ther. 2007 Jul 2;49(1264):53-5 |  Show IntroductionHide Introduction

Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019  (Issue 1581)
, hypokalemia, insomnia, and headache occurred with both formulations of lefamulin at rates similar to those ...
Lefamulin (Xenleta – Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be approved in the US; retapamulin (Altabax), a 1% topical ointment for treatment of impetigo, was approved in 2007.
Med Lett Drugs Ther. 2019 Sep 23;61(1581):145-8 |  Show IntroductionHide Introduction

Drugs for Common Bacterial Infections in Adults

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017  (Issue 1532)
(Cubicin) Occasional: GI disturbance; rash; injection site reaction; fever; headache; insomnia; dizziness ...
Bacterial infections in adults are generally treated empirically, with the antibiotic covering most, but not all, of the potential causative pathogens. For some infections, culture and sensitivity testing can guide treatment, allowing for use of narrower-spectrum antibiotics. The recommended dosages and durations of antibiotic treatment for common respiratory, skin, and urinary tract infections are listed in Tables 1-3. Infectious disease experts now recommend shorter treatment durations for many infections to reduce the development of antimicrobial resistance and minimize adverse...
Med Lett Drugs Ther. 2017 Oct 23;59(1532):171-7 |  Show IntroductionHide Introduction

Drugs for Cognitive Loss and Dementia

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
, muscle spasms, insomnia, abdominal pain, constipation, diarrhea, dizziness, abnormal dreams, and skin ...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2022 Aug 22;64(1657):129-36 |  Show IntroductionHide Introduction

Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia

   
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018  (Issue 1545)
trial and nasopharyngitis and insomnia (4% each) in tardive dyskinesia trials. In an interim analysis ...
The FDA has approved deutetrabenazine (Austedo – Teva), a vesicular monoamine transporter 2 (VMAT2) inhibitor, for treatment of chorea associated with Huntington's disease and, more recently, for treatment of tardive dyskinesia in adults. It is the second VMAT2 inhibitor to be approved for each of these indications; tetrabenazine (Xenazine, and generics) was approved earlier for Huntington's chorea and valbenazine (Ingrezza) was recently approved for treatment of adults with tardive dyskinesia.
Med Lett Drugs Ther. 2018 Apr 23;60(1545):65-8 |  Show IntroductionHide Introduction

Istradefylline (Nourianz) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020  (Issue 1591)
with placebo were constipation, dizziness, nausea, hallucinations, and insomnia. Use of istradefylline ...
The FDA has approved istradefylline (Nourianz — Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience "off" episodes. Istradefylline is the first adenosine A2A receptor antagonist to be approved in the US; it has been available in Japan since 2013.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):20-3 |  Show IntroductionHide Introduction